High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.
Identifieur interne : 000D40 ( Main/Exploration ); précédent : 000D39; suivant : 000D41High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.
Auteurs : RBID : pubmed:22381781English descriptors
- KwdEn :
- Alpha Particles (therapeutic use), Animals, Bismuth (therapeutic use), Female, Immunoconjugates (chemistry), Immunoconjugates (pharmacokinetics), Immunotherapy (methods), Indium Radioisotopes (therapeutic use), Injections, Intraperitoneal, Mice, Mice, Inbred BALB C, Molecular Weight, Peritoneum (metabolism), Time Factors.
- MESH :
- chemical , chemistry : Immunoconjugates.
- chemical , pharmacokinetics : Immunoconjugates.
- chemical , therapeutic use : Bismuth, Indium Radioisotopes.
- metabolism : Peritoneum.
- methods : Immunotherapy.
- therapeutic use : Alpha Particles.
- Animals, Female, Injections, Intraperitoneal, Mice, Mice, Inbred BALB C, Molecular Weight, Time Factors.
Abstract
Therapeutic efficacy of intraperitoneal radioimmunotherapy is dependent on the time of retention of the radioimmunoconjugates within the peritoneal cavity. Therefore, the aim of this study was to investigate intraperitoneal retention of Fab, IgG and IgM radioimmunoconjugates.
DOI: 10.1016/j.nucmedbio.2011.12.005
PubMed: 22381781
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.</title><author><name sortKey="Rauch, Christian" uniqKey="Rauch C">Christian Rauch</name><affiliation wicri:level="3"><nlm:affiliation>Department of Nuclear Medicine, Technische Universität München, 81675 Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Nuclear Medicine, Technische Universität München, 81675 Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Seidl, Christof" uniqKey="Seidl C">Christof Seidl</name></author><author><name sortKey="Schlapschy, Martin" uniqKey="Schlapschy M">Martin Schlapschy</name></author><author><name sortKey="Skerra, Arne" uniqKey="Skerra A">Arne Skerra</name></author><author><name sortKey="Morgenstern, Alfred" uniqKey="Morgenstern A">Alfred Morgenstern</name></author><author><name sortKey="Bruchertseifer, Frank" uniqKey="Bruchertseifer F">Frank Bruchertseifer</name></author><author><name sortKey="Senekowitsch Schmidtke, Reingard" uniqKey="Senekowitsch Schmidtke R">Reingard Senekowitsch-Schmidtke</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1016/j.nucmedbio.2011.12.005</idno><idno type="RBID">pubmed:22381781</idno><idno type="pmid">22381781</idno><idno type="wicri:Area/Main/Corpus">000E60</idno><idno type="wicri:Area/Main/Curation">000E60</idno><idno type="wicri:Area/Main/Exploration">000D40</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alpha Particles (therapeutic use)</term><term>Animals</term><term>Bismuth (therapeutic use)</term><term>Female</term><term>Immunoconjugates (chemistry)</term><term>Immunoconjugates (pharmacokinetics)</term><term>Immunotherapy (methods)</term><term>Indium Radioisotopes (therapeutic use)</term><term>Injections, Intraperitoneal</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Molecular Weight</term><term>Peritoneum (metabolism)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Immunoconjugates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Immunoconjugates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bismuth</term><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Peritoneum</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunotherapy</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Alpha Particles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Injections, Intraperitoneal</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Molecular Weight</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Therapeutic efficacy of intraperitoneal radioimmunotherapy is dependent on the time of retention of the radioimmunoconjugates within the peritoneal cavity. Therefore, the aim of this study was to investigate intraperitoneal retention of Fab, IgG and IgM radioimmunoconjugates.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22381781</PMID><DateCreated><Year>2012</Year><Month>06</Month><Day>22</Day></DateCreated><DateCompleted><Year>2012</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9614</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nuclear medicine and biology</Title><ISOAbbreviation>Nucl. Med. Biol.</ISOAbbreviation></Journal><ArticleTitle>High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.</ArticleTitle><Pagination><MedlinePgn>617-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nucmedbio.2011.12.005</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Therapeutic efficacy of intraperitoneal radioimmunotherapy is dependent on the time of retention of the radioimmunoconjugates within the peritoneal cavity. Therefore, the aim of this study was to investigate intraperitoneal retention of Fab, IgG and IgM radioimmunoconjugates.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Female Balb/c mice were injected with 213Bi- or 111In-labeled IgM, IgG and recombinant Fab conjugates intraperitoneally or intravenously. At different time points after injection, whole body distribution of radionuclides was imaged using a gamma camera. Distribution of radionuclides in selected organs was determined via γ-counting after sacrifice. Biological half-lives of the conjugates were calculated from whole body activities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After i.p. injection 213Bi-Fab rapidly accumulated in the kidneys indicative of glomerular filtration and reabsorption. Accumulation of 213Bi-IgG in the kidneys was significantly lower. 213Bi-IgM showed a striking accumulation in the liver 180 min after i.p. injection. 111In-IgG persisted in the circulation up to 72 h both after i.p. and i.v. injection. 111In-IgM showed a continuous accumulation in the liver. Moreover, 111In-IgM was significantly higher 24 h after i.v. injection than i.p. injection both in liver and spleen. These differences could be confirmed via scintigraphy. After injection of 111In-IgG differences in scintigraphic images between i.v. and i.p. were clearly visible only at 3 h. Biological half lives were 24 h, 45 h and 165 h for 111In-IgM, 111In-Fab and 111In-IgG, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Retention of radioimmunoconjugates in the peritoneal cavity positively correlates with the molecular mass of the antibody. Therefore, IgM radioimmunoconjugates should be preferably used in radioimmunotherapy of free floating tumor cells and small tumor cell clusters in the ascites of the peritoneal cavity.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Affiliation>Department of Nuclear Medicine, Technische Universität München, 81675 Munich, Germany.</Affiliation></Author><Author ValidYN="Y"><LastName>Seidl</LastName><ForeName>Christof</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schlapschy</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Skerra</LastName><ForeName>Arne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Morgenstern</LastName><ForeName>Alfred</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bruchertseifer</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Senekowitsch-Schmidtke</LastName><ForeName>Reingard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nucl Med Biol</MedlineTA><NlmUniqueID>9304420</NlmUniqueID><ISSNLinking>0969-8051</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Immunoconjugates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>U015TT5I8H</RegistryNumber><NameOfSubstance>Bismuth</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Alpha Particles</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Bismuth</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunoconjugates</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Peritoneum</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0969-8051(11)00307-6</ArticleId><ArticleId IdType="doi">10.1016/j.nucmedbio.2011.12.005</ArticleId><ArticleId IdType="pubmed">22381781</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22381781
|texte= High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22381781" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |